Literature DB >> 27012810

Individualized Tamoxifen Dose Escalation: Confirmation of Feasibility, Question of Utility.

Daniel L Hertz1, James M Rae2.   

Abstract

Tamoxifen may require metabolic activation to endoxifen for efficacy in treating hormone receptor-positive breast cancer. Dose escalation in patients with low endoxifen concentrations could enhance treatment efficacy. This approach is clinically feasible, and successfully increases endoxifen concentrations; however, it is unknown whether patients benefit from individualized tamoxifen dose escalation. Clin Cancer Res; 22(13); 3121-3. ©2016 AACRSee related article by Fox et al., p. 3164. ©2016 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27012810      PMCID： PMC4930675          DOI： 10.1158/1078-0432.CCR-16-0370

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  12 in total

1.  Dose-adjustment study of tamoxifen based on CYP2D6 genotypes in Japanese breast cancer patients.

Authors:  Kazuma Kiyotani; Taisei Mushiroda; Chiyo K Imamura; Yusuke Tanigawara; Naoya Hosono; Michiaki Kubo; Mitsunori Sasa; Yusuke Nakamura; Hitoshi Zembutsu
Journal:  Breast Cancer Res Treat       Date:  2011-09-23       Impact factor: 4.872

2.  Adjusting the dose of tamoxifen in patients with early breast cancer and CYP2D6 poor metabolizer phenotype.

Authors:  Eduardo Martinez de Dueñas; Enrique Ochoa Aranda; Isabel Blancas Lopez-Barajas; Teresa Ferrer Magdalena; Fernando Bandrés Moya; Luis Miguel Chicharro García; José A Gómez Capilla; Mercedes Zafra Ceres; Tomás de Haro; Regina Romero Llorens; Carlos Ferrer Albiach; Rafael Ferriols Lisart; Dolores Chover Lara; Angela López Rodríguez; Javier Munárriz Ferrandis; Santiago Olmos Antón
Journal:  Breast       Date:  2014-03-29       Impact factor: 4.380

3.  Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study.

Authors:  William J Irvin; Christine M Walko; Karen E Weck; Joseph G Ibrahim; Wing K Chiu; E Claire Dees; Susan G Moore; Oludamilola A Olajide; Mark L Graham; Sean T Canale; Rachel E Raab; Steven W Corso; Jeffrey M Peppercorn; Steven M Anderson; Kenneth J Friedman; Evan T Ogburn; Zeruesenay Desta; David A Flockhart; Howard L McLeod; James P Evans; Lisa A Carey
Journal:  J Clin Oncol       Date:  2011-07-18       Impact factor: 44.544

4.  Increasing tamoxifen dose in breast cancer patients based on CYP2D6 genotypes and endoxifen levels: effect on active metabolite isomers and the antiestrogenic activity score.

Authors:  M F Barginear; M Jaremko; I Peter; C Yu; Y Kasai; M Kemeny; G Raptis; R J Desnick
Journal:  Clin Pharmacol Ther       Date:  2011-09-07       Impact factor: 6.875

5.  Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes.

Authors:  L Madlensky; L Natarajan; S Tchu; M Pu; J Mortimer; S W Flatt; D M Nikoloff; G Hillman; M R Fontecha; H J Lawrence; B A Parker; A H B Wu; J P Pierce
Journal:  Clin Pharmacol Ther       Date:  2011-03-23       Impact factor: 6.875

6.  CYP3A4 and seasonal variation in vitamin D status in addition to CYP2D6 contribute to therapeutic endoxifen level during tamoxifen therapy.

Authors:  Wendy A Teft; Inna Y Gong; Brian Dingle; Kylea Potvin; Jawaid Younus; Theodore A Vandenberg; Muriel Brackstone; Francisco E Perera; Yun-Hee Choi; Guangyong Zou; Robin M Legan; Rommel G Tirona; Richard B Kim
Journal:  Breast Cancer Res Treat       Date:  2013-04-12       Impact factor: 4.872

7.  Dose Escalation of Tamoxifen in Patients with Low Endoxifen Level: Evidence for Therapeutic Drug Monitoring-The TADE Study.

Authors:  Peter Fox; Rosemary L Balleine; Clara Lee; Bo Gao; Bavanthi Balakrishnar; Alexander M Menzies; Shang Heng Yeap; Sayed Sahanawaz Ali; Val Gebski; Pamela Provan; Sally Coulter; Christopher Liddle; Rina Hui; Richard Kefford; Jodi Lynch; Mark Wong; Nicholas Wilcken; Howard Gurney
Journal:  Clin Cancer Res       Date:  2016-02-04       Impact factor: 12.531

8.  Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.

Authors:  C Davies; J Godwin; R Gray; M Clarke; D Cutter; S Darby; P McGale; H C Pan; C Taylor; Y C Wang; M Dowsett; J Ingle; R Peto
Journal:  Lancet       Date:  2011-07-28       Impact factor: 79.321

9.  CYP2D6 genotype- and endoxifen-guided tamoxifen dose escalation increases endoxifen serum concentrations without increasing side effects.

Authors:  V O Dezentjé; F L Opdam; H Gelderblom; J Hartigh den; T Van der Straaten; R Vree; E Maartense; C H Smorenburg; H Putter; A S Dieudonné; P Neven; C J H Van de Velde; J W R Nortier; H-J Guchelaar
Journal:  Breast Cancer Res Treat       Date:  2015-09-14       Impact factor: 4.872

10.  Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer.

Authors:  P Saladores; T Mürdter; D Eccles; B Chowbay; N K Zgheib; S Winter; B Ganchev; B Eccles; S Gerty; A Tfayli; J S L Lim; Y S Yap; R C H Ng; N S Wong; R Dent; M Z Habbal; E Schaeffeler; M Eichelbaum; W Schroth; M Schwab; H Brauch
Journal:  Pharmacogenomics J       Date:  2014-08-05       Impact factor: 3.550
View more
  5 in total

1.  CYP2D6 genotype is not associated with survival in breast cancer patients treated with tamoxifen: results from a population-based study.

Authors:  D L Hertz; K M Kidwell; S G Hilsenbeck; S Oesterreich; C K Osborne; S Philips; C Chenault; R J Hartmaier; T C Skaar; M J Sikora; J M Rae
Journal:  Breast Cancer Res Treat       Date:  2017-07-20       Impact factor: 4.872

2.  Individualized Tamoxifen Dose Escalation-Response.

Authors:  Daniel L Hertz; James M Rae
Journal:  Clin Cancer Res       Date:  2016-12-15       Impact factor: 12.531

Review 3.  Pharmacogenomics Guided-Personalization of Warfarin and Tamoxifen.

Authors:  Theodore J Wigle; Laura E Jansen; Wendy A Teft; Richard B Kim
Journal:  J Pers Med       Date:  2017-12-13

4.  Improved Prediction of Endoxifen Metabolism by CYP2D6 Genotype in Breast Cancer Patients Treated with Tamoxifen.

Authors:  Werner Schroth; Stefan Winter; Thomas Mürdter; Elke Schaeffeler; Diana Eccles; Bryony Eccles; Balram Chowbay; Chiea C Khor; Arafat Tfayli; Nathalie K Zgheib; Michel Eichelbaum; Matthias Schwab; Hiltrud Brauch
Journal:  Front Pharmacol       Date:  2017-08-24       Impact factor: 5.810

5.  Predicting steady-state endoxifen plasma concentrations in breast cancer patients by CYP2D6 genotyping or phenotyping. Which approach is more reliable?

Authors:  Milena Gusella; Felice Pasini; Barbara Corso; Laura Bertolaso; Giovanni De Rosa; Cristina Falci; Yasmina Modena; Carmen Barile; Donatella Da Corte Z; AnnaPaola Fraccon; Silvia Toso; Elisabetta Cretella; Antonella Brunello; Caterina Modonesi; Romana Segati; Cristina Oliani; Nadia Minicuci; Roberto Padrini
Journal:  Pharmacol Res Perspect       Date:  2020-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.